Latest News:
  • FDA Approves Oxbryta™ (Voxelotor), the First Medicine Specifically Targeting the Root Cause of Sickle Cell Disease
  • TIF will coordinate efforts for patients’ information on Reblozyl in 62 countries
  • New and Updated Data on Key Thalassaemia & SCD Pipeline Therapies at the American Society of Hematology (ASH) 2019 Annual Meeting – 7-10 December 2019
  • Deferasirox Mylan: A new generic drug for the treatment of iron overload in β-thalassaemia major obtained approval by the EMA
  • US government & Gates Foundation pledge $200 million to bring gene therapies to patients with Sickle Cell Disease & HIV
ardeelenfrit

TIFTIF

  • About
  • Education
  • Country work
  • Positions & Policies
  • Projects
  • Publications
  • News & Events
  • Contact
Home » Clinical Trials – Press Announcements

Clinical Trials – Press Announcements

Protagonist Therapeutics (PTGX) Announces FDA Granted Orphan Drug Designation for PTG-300 for Treatment of Beta-Thalassemia 

Montco biopharm firm begins human studies of iron overload therapy

La Jolla Pharmaceutical Company Announces Initiation of Multicenter, Randomized, Phase 2 Clinical Study of LJPC‑401 in Patients with Hereditary Hemochromatosis

 

2018-03-13
Vicky Antoniadou

Quick Links

  • For Patients
  • For Healthcare Professionals
  • For Associations
  • For Supporters
  • Our Members
  • Useful Links
  • Sitemap

Quick links

  • For Patients
  • For Healthcare Professionals
  • For Associations
  • For Supporters
  • Our Members
  • Useful Links
  • Sitemap

Design & Development

Featured Video

More videos

Subscribe to our newsletter

Download the Apps

ThaliMe App


Transparency Statement | Privacy Policy

Copyright TIF © 2019

Cookies

This site uses cookies. Find out more